Although other epigenetic regulators, such as the DNA methyltransferase inhibitor 5-Aza-dc, have been used extensively in multiple cancer types to effectively target glycogenes and glycosylation enzymes to slow tumor progression [10–12], the effects of HDAC inhibitors on glycosylation, oncogenic phenotype, and chemotherapeutic response have not been extensively investigated. This evidence concerns the gene HDAC9 and cancer.